MNPR

MKT CAP:$351M

Monopar Therapeutics Inc.

Market Cap

$351M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$52.85-$13.16 (-19.94%)

Apr 24, 2026

Company Details

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride muc...

CEO

Chandler D. Robinson

IPO Date

Dec 19, 2019

Website

www.monopartx.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$14M

EPS (Diluted)

-$1.99

Free Cash Flow

-$12M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q1 2026

May 12, 2026

PENDING

Q4 2025

Mar 27, 2026

$0EPS -$0.78

Q3 2025

Nov 13, 2025

$0EPS -$0.48

Q2 2025

Aug 12, 2025

$0EPS -$0.35

Q1 2025

May 13, 2025

$0EPS -$0.38

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$2M
Q2 22	$0	$0	-$3M
Q3 22	$0	$0	-$2M
Q4 22	$0	$0	-$3M
Q1 23	$0	$0	-$3M
Q2 23	$0	$0	-$2M
Q3 23	$0	$0	-$2M
Q4 23	$0	$0	-$2M
Q1 24	$0	$0	-$2M
Q2 24	$0	$0	-$2M
Q3 24	$0	$0	-$2M
Q4 24	$0	$0	-$11M
Q1 25	$0	$0	-$3M
Q2 25	$0	$0	-$3M
Q3 25	$0	$0	-$4M
Q4 25	$0	$0	-$6M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$2M	-$2M
Q2 22	-$1M	-$1M
Q3 22	-$2M	-$2M
Q4 22	-$1M	-$1M
Q1 23	-$2M	-$2M
Q2 23	-$2M	-$2M
Q3 23	-$2M	-$2M
Q4 23	-$2M	-$2M
Q1 24	-$2M	-$2M
Q2 24	-$2M	-$2M
Q3 24	-$1M	-$1M
Q4 24	-$2M	-$2M
Q1 25	-$6M	-$6M
Q2 25	-$1M	-$1M
Q3 25	-$2M	-$2M
Q4 25	-$3M	-$3M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$3
Q3 22	$2
Q4 22	$4
Q1 23	$0
Q2 23	$2
Q3 23	$0
Q4 23	$1
Q1 24	$0
Q2 24	$2
Q3 24	$0
Q4 24	$0
Q1 25	$4
Q2 25	$1
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	+29.7%
Q2 22	—	+32.1%
Q3 22	—	-2.1%
Q4 22	—	+8.5%
Q1 23	—	+2.8%
Q2 23	—	-15.7%
Q3 23	—	-14.2%
Q4 23	—	-34.3%
Q1 24	—	-31.7%
Q2 24	—	-23.2%
Q3 24	—	-23.8%
Q4 24	—	+479.2%
Q1 25	—	+86.9%
Q2 25	—	+80.8%
Q3 25	—	+159.9%
Q4 25	—	-44.4%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$499.8K	—
Q2 22	$357.3K	—
Q3 22	$390.7K	—
Q4 22	$393.4K	—
Q1 23	$476.2K	—
Q2 23	$473.3K	—
Q3 23	$474.1K	—
Q4 23	$474.2K	—
Q1 24	$328.7K	—
Q2 24	$334.4K	—
Q3 24	$199.1K	—
Q4 24	$278.6K	—
Q1 25	$1M	—
Q2 25	$1M	—
Q3 25	$1M	—
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A	SG&A
Q1 22	$2M	$779.3K	—
Q2 22	$2M	$684.9K	—
Q3 22	$2M	$675.1K	—
Q4 22	$2M	$806.0K	—
Q1 23	$2M	$871.7K	—
Q2 23	$2M	$733.5K	—
Q3 23	$1M	$749.5K	—
Q4 23	$1M	$876.4K	—
Q1 24	$966.1K	$757.3K	—
Q2 24	$1M	$657.8K	—
Q3 24	$984.3K	—	$590.6K
Q4 24	$10M	—	$1M
Q1 25	$2M	$2M	—
Q2 25	$2M	$2M	—
Q3 25	$3M	—	$2M
Q4 25	$4M	—	$2M

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 21	$20M	$0	$20M
Q1 22	$18M	$0	$18M
Q2 22	$16M	$0	$16M
Q3 22	$14M	$0	$14M
Q4 22	$8M	$5M	$13M
Q1 23	$6M	$6M	$12M
Q2 23	$7M	$3M	$10M
Q3 23	$6M	$3M	$8M
Q4 23	$7M	$0	$7M
Q1 24	$8M	$985.7K	$9M
Q2 24	$6M	$998.8K	$7M
Q3 24	$6M	$0	$6M
Q4 24	$46M	$14M	$60M
Q1 25	$40M	$15M	$55M
Q2 25	$40M	$14M	$53M
Q3 25	$128M	$16M	$144M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	13M	+0.2%	+3.8%
Q2 22	13M	+0.2%	+0.5%
Q3 22	13M	+1.0%	+1.4%
Q4 22	13M	+1.5%	+2.9%
Q1 23	13M	+1.2%	+4.0%
Q2 23	13M	+2.4%	+6.2%
Q3 23	14M	+5.2%	+10.7%
Q4 23	15M	+5.6%	+15.1%
Q1 24	16M	+7.2%	+21.9%
Q2 24	11M	-28.1%	-14.4%
Q3 24	11M	0.0%	-18.7%
Q4 24	11M	0.0%	-23.0%
Q1 25	7M	-39.2%	-56.3%
Q2 25	7M	+0.2%	-39.1%
Q3 25	7M	+1.8%	-38.0%
Q4 25	7M	-6.1%	-41.7%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	$0	10
Q2 22	$0	10
Q3 22	$0	10
Q4 22	$0	12
Q1 23	$0	12
Q2 23	$0	12
Q3 23	$0	12
Q4 23	$0	10
Q1 24	$0	10
Q2 24	$0	10
Q3 24	$0	10
Q4 24	$0	16
Q1 25	$0	16
Q2 25	$0	16
Q3 25	$0	16
Q4 25	$0	22

Revenue / Employee